Whilst retatrutide is not currently available in the UK outside of clinical trials, your GP can help you understand which licensed treatments may be appropriate for your individual circumstances, taking into account your medical history, current medications, and weight management goals
These trials, expected to conclude by February 2026, will provide critical data on sustained weight loss, cardiovascular outcomes, and kidney function
Dulaglutide and exendin-4 have shown positive effects on SM atrophy by suppressing muscle atrophy factors and myostatin and enhancing myogenic factors
The ease of ordering medicines in the comfort of the patients home from a wide range of options increases the demand for online pharmacies
When interpreting our results, it is important to highlight that GLP-1RAs were associated with a reduced incidence of anxiety disorders, autism, bulimia nervosa, PTSD, and schizophrenia